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Angiotensin I–converting enzyme inhibitors (ACEi), which are used to treat common cardiovascular diseases, are
associated with a potentially life-threatening adverse reaction known as angioedema (AE-ACEi). We have previously
documented a significant association between AE-ACEi and low plasma aminopeptidase P (APP) activity. With
eight large pedigrees, we hereby demonstrate that this quantitative trait is partially regulated by genetic factors.
We tested APP activity using a variance-component QTL analysis of a 10-cM genomewide microsatellite scan
enriched with seven markers over two candidate regions. We found significant linkage (LOD p 3.75) to a locus
that includes the XPNPEP2 candidate gene encoding membrane-bound APP. Mutation screening of this QTL
identified a large coding deletion segregating in one pedigree and an upstream single-nucleotide polymorphism (C–
2399A SNP), which segregates in the remaining seven pedigrees. Measured genotype analysis strongly suggests that
the linkage signal for APP activity at this locus is accounted for predominantly by the SNP association. In a separate
case-control study (20 cases and 60 controls), we found significant association of this SNP to ACEi-induced AE
( ). In conclusion, our findings provide supporting evidence that the C-2399A variant in XPNPEP2 isPp .0364
associated with reduced APP activity and a higher incidence of AE-ACEi.
Introduction
Angiotensin I–converting enzyme inhibitors (ACEi) are
a class of drugs used by 140 million patients worldwide
for the treatment of cardiovascular diseases such as hy-
pertension, congestive heart failure, and diabetes (Unger
and Gohlke 1994; Brown and Vaughan 1998). Angioe-
dema (AE) associated with ACEi therapy (AE-ACEi) is
a potentially fatal adverse event that affects 0.1%–0.7%
of white patients (Israili and Hall 1992; Vleeming et al.
1998) and is four to five times more prevalent among
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African Americans (Brown et al. 1996; Coats 2002).
This racial difference suggests that genetic factors mod-
ulate AE risk, but environmental factors are also im-
portant, because smokers taking ACEi have an increased
susceptibility to AE (Coats 2002; Kostis et al. 2004).
The incidence of AE-ACEi is likely underestimated be-
cause the clinical symptoms can develop years after start-
ing ACEi therapy, thus obscuring the adverse event’s
relationship with the drug and often leading to misdi-
agnosis (Agostoni et al. 2004).
A majority of AE-ACEi cases do not respond to an-
tihistamines or corticosteroids, indicating that these
cases are not allergic reactions (Agostoni and Cicardi
2001). Currently, there is no effective treatment for AE-
ACEi and no method for identifying individuals with
increased susceptibility to this adverse reaction. Better
understanding of the pathogenetic mechanism under-
lying this type of AE may also have significant impli-
cations for AE associated with other vasopeptidase in-
hibitors (i.e., Omapatrilat), which block the activities
618 Am. J. Hum. Genet. 77:617–626, 2005
of both ACE and neutral endopeptidase (NEP). The AE
risk associated with these drugs is even higher than with
ACEi (Coats 2002) and has curtailed the regulatory ap-
proval for usage of these vasopeptidase inhibitors to
treat cardiovascular diseases.
Previous reports have suggested that bradykinin (BK),
a potent vasodilatory and proinflammatory nonapep-
tide, plays a central role in the pathophysiology of AE-
ACEi (Israili and Hall 1992; Nussberger et al. 1998).
BK is rapidly degraded in the plasma of healthy indi-
viduals by angiotensin I–converting enzyme (ACE) and
aminopeptidase P (APP) (Bhoola et al. 1992). Kininase
I enzymes normally transform a minute fraction (3.5%)
of BK into its active metabolite, des-arginine9-brady-
kinin (des-Arg9-BK) (Blais et al. 2000). This carboxy-
truncated metabolite is, in turn, broken down by APP
and ACE (Cyr et al. 2001). In the presence of ACE
inhibition, however, kininase I activity is increased
(transforms 28% of BK into des-Arg9-BK), and APP acts
as the major metabolizing enzyme of both BK and des-
Arg9-BK (Blais et al. 2000).
An increase of BK has been measured in the plasma
of patients during episodes of AE-ACEi, but, unlike he-
reditary forms of AE (MIM 106100), there is no in-
crease in cleavage of the BK precursor, high-molecular-
weight kininogen (HK) (Nussberger et al. 1998; Ago-
stoni et al. 1999; Cugno et al. 2003). This suggests that
impaired BK metabolism, rather than increased BK pro-
duction, plays an important role in AE-ACEi. We pre-
viously reported significantly lower plasma APP activ-
ities in patients with a history of AE-ACEi, which is
strongly correlated with a significant decrease in des-
Arg9-BK degradation in vitro (Blais et al. 1999a; Adam
et al. 2002; Molinaro et al. 2002). Blais et al. demon-
strated that half of AE-ACEi cases have an enzyme de-
fect involved in des-Arg9-BK metabolism (Blais et al.
1999b). Accumulated levels of des-Arg9-BK have been
shown to cause proinflammatory effects in vivo (Blais
et al. 1997; Blais et al. 1999a). One study reported that
ACEi patients who received subcutaneous injections of
the APP inhibitor Apstatin developed local inflamma-
tions (Kim et al. 2000). Thus, previous data indicate
that reduced plasma APP activity may predict increased
risk for AE associated with ACEi therapy.
The aim of this study is to determine whether plasma
APP activity is regulated by genetic factors and to iden-
tify the QTL or QTLs that confer susceptibility to AE-
ACEi. There are two known APP enzymes in humans:
membrane-bound (mAPP) and cytosolic (cAPP). The
gene encoding the former is XPNPEP2 (MIM 300145),
localized to chromosome Xq26.1 (Sprinkle et al. 1998),
and the latter is the product of XPNPEPL (MIM
602443) on chromosome 10q25.1 (Sprinkle et al.
2000). Although these represent good candidate genes
for the interindividual variability in plasma APP activity,
other genetic loci may serve as important regulators.
Plasma APP activity has been shown to form a contin-
uous distribution in the general population (Cyr et al.
2001), suggesting that plasma APP activity is a complex
quantitative trait likely influenced by multiple genetic
loci and nongenetic factors (e.g., smoking and hormone
replacement therapy [Gallagher et al. 1999]). Identifi-
cation of the genetic factors underlying reduced plasma
APP activity would provide a better understanding of
the pathogenesis of AE-ACEi and could facilitate the
development of a clinical assay to detect those individ-
uals with greater AE risk.
Subjects and Methods
Blood and Plasma Samples
The ethics committees from Centre Hospitalier de
l’Universite de Montreal, Institut de Cardiologie de
Montreal, and McGill University, all in Montreal, re-
viewed and approved all protocols involving human sub-
jects. Informed consent was obtained from all partic-
ipants. DNA extraction from blood was performed
following a standardized protocol (Gentra Systems).
Participants
Cohort 1 (fig. 1a), composed of five white pedigrees
(88 DNA samples), was collected for a genomewide
microsatellite scan, followed by a variance-component
linkage analysis for APP activity. Cohort 2 (fig. 1b), con-
sisting of three white pedigrees (35 DNA samples), was
subsequently selected for genotyping of 11 microsatellite
markers (table 1), which cover four genomic regions that
provided LOD scores 11 in the linkage analysis of cohort
1 and the locus including the XPNPEPL candidate gene.
Plasma samples were also collected from all 123 partic-
ipants for characterization of APP activity. The kindreds
were selected from Canada (Montreal) and France on
the basis of the presence of one individual in each family
with a history of AE and/or another acute adverse effect
related to ACEi therapy, anaphylactoid reactions (AR-
ACEi) (Bright et al. 1999). The clinical diagnosis was
not considered for linkage analysis because of lack of
power. Instead, plasma APP activity measurements were
used as the quantitative trait in a variance-component
linkage analysis.
DNA from 20 independent AE-ACEi cases (table A1
[online only]) was extracted for mutation screening ex-
periments. All subjects were whites with histories of AE-
ACEi and origins in Canada ( ), Belgium ( ),np 7 np 3
or the United States ( ). Plasma samples werenp 10
available for all AE subjects except two from the United
States. The onset of clinical symptoms ranged from a
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Figure 1 Cohorts included in variance-component linkage analysis. One member of each kindred, depicted in black, developed AE and/
or AR associated with ACEi therapy. All available members were quantified for plasma APP activity, shown as numbers that represent units
of arginine released per minute per milliliter of plasma. Genotypes of the C-2399A SNP upstream of XPNPEP2 are shown as C/C, C/A, or A/
A for females, and C or A for males. a, DNA samples from cohort 1 were included in a genomewide microsatellite scan, which was analyzed
for linkage using a variance-component method (SOLAR program). b, Eleven genome-scanned markers were genotyped in cohort 2 to further
evaluate linkage. A large deletion (DEL) in XPNPEP2 segregates in pedigree VI.
few hours to 8 years after starting ACEi therapy. In
addition, we collected three unrelated white controls to
match each AE patient for country of origin and gender
( ). Controls from Belgium and Canada had nonp 60
history of ACEi therapy, whereas the medical histories
were unknown for US controls. Controls were not
matched for age because we did not find age effects in
our samples, which is in agreement with previous find-
ings (Cyr et al. 2001).
Quantification of Plasma APP Activity
APP activity was measured in plasma with modifi-
cation of an assay described elsewhere (Simmons and
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Figure 2 Results of the variance-component QTL analyses in
the five pedigrees of cohort 1. All results were corrected empirically
for a 0.05. a, String diagram of autosomal multipoint results, LODs
11, are shown next to a LOD scale. b, Two-point linkage analysis
results including chromosome X.
Table 1
Variance-Component Two-Point QTLs for Markers Genotyped in Cohorts 1 and 2
MARKER
POSITION
(cM)
CHROMOSOME
BAND
LOD
Cohorts 1 and 2
(8 Pedigrees) Cohort 1 Only
D6S1017 63.3 6p21.1 .97 2.62
D6S1280 73.1 6p12.3 .18 1.09
D6S1056 102.8 6q16.1 1.32 1.68
D8S277 8.0 8p23.1 .22 .69
D8S373 164.5 8q24.3 1.72 1.76
D9S925 32.2 9p22.2 .16 1.71
D9S1122 75.9 9q21.2 .13 .76
Markers flanking candidates:
D10S1220 70.2 10q11.23 .24 .74
DXS8057 136.4 Xq25 2.10 1.82
DXS1047 143.2 Xq25 2.04 .28
XPNPEP2_CA 146.0 Xq25 3.75 2.15
NOTE.—Eleven microsatellite markers that were already part of the analysis in cohort 1 were
genotyped in cohort 2 to cover the four loci that provided LOD scores 11 in cohort 1 and the region
proximal to the XPNPEPL candidate gene (D10S1220).
Orawski 1992; Blais et al. 1999a). Our assay used the
synthetic substrate arginine-proline-proline. Plasma APP
activity is expressed as nanomoles of arginine released
per minute per milliliter of plasma sample (1 unit p 1
nmol/min/ml).
Genome Scan and Microsatellite Genotyping
A 10-cM genomewide microsatellite scan (marker
panel SS4 on the ABI-3700 DNA analyzer at the Ge-
nome Quebec Innovation Centre, Montreal), enriched
for seven markers flanking the two APP candidate genes
on chromosomes 10 and X (D10S534, D10S1741,
D10S562, DXS1212, DXS8057, XPNPEP2_CA, and
DXS1047), was performed on cohort 1 (total of 397
microsatellite markers). Primers for the XPNPEP2_CA
repeat marker located upstream of XPNPEP2 (∼4 kb
were designed for this study) were sense 5′-GCTCTTTC-
CCCCTGCTGTGT-3′ and antisense 5′-GGTGCTGTT-
GGGTGCCTCATC-3′.
Genotyping of the 11 genome-scanned markers in co-
hort 2 was conducted in our laboratory. Genomic DNA
was amplified by radiolabeled (a-35S-dATP) PCR. The
products were separated by electrophoresis on 6% de-
naturing polyacrylamide gels. The alleles were sized by
comparison to the M13mp18 sequence ladder, and each
individual was assigned a genotype. Marker-allele sizes
and frequencies were obtained from the Fondation Jean
Dausset CEPH database.
Statistical Analyses
The SOLAR (Sequential Oligogenic Linkage Analysis
Routines, v. 2.1.4) (Almasy and Blangero 1998) program
was used to estimate heritability of plasma APP activity
and to perform a variance-component linkage analysis.
Age and sex were considered as covariates, but were not
significant (P 1 .05). APP activity was transformed for
normality to avoid convergence failure of SOLAR by
using the Box-Cox transformation (Box and Cox 1964),
such that T(APP)p {[(APP 1)# 0.40 1]/0.40}#
. The two-point (all chromosomes) and multipoint4
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(autosomes only) variance-component linkage analyses
were conducted for Box-Cox transformed plasma APP
activity in cohorts 1 and 2. Empirical LOD adjustment
based on 10,000 simulations was used for all linkage
analyses. QTL results of the genomewide scan for the
five pedigrees in cohort 1 were adjusted with an empir-
ical LOD factor of 0.98220 (results shown in fig. 2).
QTL results of cohorts 1 and 2 were corrected with an
empirical LOD adjustment factor of 0.74595 (table 1).
A measured genotype approach using variance-
component analysis (Soria et al. 2000) in SOLAR was
used to test for the C-2399A SNP genotype-specific
differences in plasma APP-activity means at the
XPNPEP2_CA marker. This approach accounts for the
different relationships among family members in per-
forming association on the measured genotypes and
quantitative traits (Box-Cox transformed plasma APP
activity). The three C-2399A SNP genotypes, CC, CA,
and AA, were coded as 1, 0, and 1 in females, re-
spectively, and the C and A hemizygous genotypes in
males as 1 and 1, respectively. The measured genotype
test was conducted on all families except pedigree VI,
which segregates the coding deletion accounting for the
APP variation in this family. Other statistical analyses
were conducted in SAS (v. 9.1.3). All tests were two-
sided.
Mutation Detection
Oligonucleotides for PCR were designed from the
genomic sequences for human XPNPEP2 (accession
number AL023653) and XPNPEPL (accession number
AL354951), obtained from the National Center for Bio-
technology Information (NCBI) database. The exons, 5′
and 3′ UTRs of both candidate genes, were amplified
using genomic DNA and radiolabeled deoxyadenosine
triphosphate for single-stranded conformational poly-
morphism (SSCP) analysis. Electrophoresis of PCR prod-
ucts was performed on 9.5% polyacrylamide (5% glyc-
erol) and on 50% mutation detection enhancement gels
(Biowhittaker Molecular Applications), followed by au-
toradiography. Samples showing altered migration pat-
terns were selected for sequencing. All sequencing was
performed at the Genome Quebec Innovation Centre in
Montreal. Variations that altered a restriction enzyme
digestion site were genotyped in additional individuals
using RFLP assays. The silent variant in exon 6 of
XPNPEP2 (SNP rs3747343) was genotyped by EcoNI
digestion.
The C-2399A SNP was genotyped using a modifica-
tion of the allele-specific PCR assay described elsewhere
(Germer and Higuchi 1999). This required three PCR
primers for each polymorphic site (sequences available
upon request): one common and two allele-specific ol-
igonucleotides. The allele-specific primers differed only
at the position of the 3′-most nucleotide. Two standard
PCRs were performed using the common primer and
either one of the allele-specific primers. Products were
visualized on 1.5% agarose gels by electrophoresis.
mRNA Analysis
Extraction of total RNA from suspended lymphoblast
cells was performed following a standardized protocol
(Qiagen). Synthesis of cDNA required two steps: (1) an-
nealing oligoDT primers and random hexamers to the
RNA template in an initial reaction mix (3 mg of total
RNA, 1 mg each of oligoDT primers and random hex-
amers, and HPLC-grade water), incubated at 70C for
3 min; and (2) extension with the addition of a second
reaction (1 ml of Moloney murine leukemia virus reverse
transcriptase [100 U], 10 ml of 5# First Strand Buffer,
5 ml of 0.1 M DTT, 1 ml of RNase Inhibitor, and 2 ml
of dNTP [25 mM]), incubated at 37C for 1 h. Primer
pairs for PCR amplification of cDNA were designed
from the transcript sequence of the human XPNPEP2
gene (accession number U90724), obtained from the
NCBI database. We applied a nested PCR protocol for
amplification of the cDNA to compensate for the low
gene expression of XPNPEP2 in lymphoblasts (Venema
et al. 1997). Products from the first PCR were diluted
30-fold and then used as template DNA in the second
PCR. Amplified products were visualized on 1.5% aga-
rose gels and then sequenced.
Results
Quantification of Plasma APP Activity
The mean plasma APP activity (SE) among our AE-
ACEi cases was 13  3 units (table 2). There was a
nonsignificant sex difference (t test, ) withPp .2549
mean APP values (SE) of 15  4 units for women
and 9  6 units for men. These mean values for AE-
ACEi patients differ from those previously reported in
healthy whites (24 9 units and 19 7 units in women
and men, respectively) (Cyr et al. 2001). Moreover, the
majority (67%) of our AE-ACEi cases have APP values
of !10 units, which is comparatively more than the 10%
reported elsewhere for the general population (Cyr et al.
2001). However, a third of our affected patients have
normal or high plasma APP activity (20 units), sug-
gesting that additional factors are likely involved in de-
termining risk to AE-ACEi.
Mutation Screening of Candidate Genes
DNA from 10 unrelated individuals with plasma APP
activities !10 units and histories of AE-ACEi were
screened for mutations in XPNPEP2 and XPNPEPL
by SSCP. A band variant was detected in exon 6 of
XPNPEP2 in four individuals. Sequencing revealed a
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Table 2
C-2399A SNP Genotypes in ACEi-Associated AE Cases and Matched Controls
C-2399A SNP GENOTYPE
AE-ACEi CASES
( )np 20
CONTROLS
( )np 60
No. of Males No. of Females
Mean APP  SE
(units) No. of Males No. of Females
CC or C 4 8 18  4 18 31
CA  4 10  5  8
AA or A 3 1 2  2 3 0
All 13  3
NOTE.—Mean APP activity is represented as units of arginine released per minute per milliliter of plasma sample.
TrC substitution (SNP rs3747343), which does not re-
sult in an amino acid change. Genotyping by RFLP anal-
ysis in the family members of these cases and in 20
healthy individuals showed no correlation between this
variant and plasma APP activity. No other sequence var-
iants in the candidate genes were detected in these
subjects.
Given the absence of a causative mutation, we con-
cluded that, if a functional variant conferring risk to AE-
ACEi exists within these candidate loci, it might be lo-
cated in the regulatory regions affecting transcription,
splicing, or message stability. Alternatively, APP activity
might be regulated by other genetic loci. For example,
variants in genes coding for transcription factors might
modulate expression of the APP coding gene(s). Ge-
nomewide studies in yeast have shown that 75% of tran-
scripts are regulated by trans-acting elements (Yvert et
al. 2003). Previous studies have also shown that ex-
pression differences in humans can be explained by ge-
netic variations located elsewhere in the genome (e.g.,
Wilm’s Tumor [Discenza and Pelletier 2004]). Thus, we
conducted a genomewide scan and variance-component
linkage analyses, in addition to further mutation screen-
ing experiments involving additional AE-ACEi cases, to
identify other potential genetic loci regulating APP
activity.
Variance-Component Linkage Analysis
Cohort 1 (fig. 1a), included in the genome scan and
characterized for plasma APP activities, was tested for
variance-component QTL analysis using SOLAR. The
mean of the transformed trait in the five pedigrees was
16.8 units, with SD of 6.3 units, skewness of 0.17
units, and kurtosis of 0.14 units. Heritability of APP
activity was estimated at 37.5%  26.5% (Pp
), indicating that the observed phenotypic vari-.0336
ability within these families partly results from genotypic
differences. The genome scan performed on cohort 1
resulted in the identification of three loci with LOD
scores 11 in multipoint linkage analysis (fig. 2a) on chro-
mosomes 6, 8, and 9, and one region on chromosome
X that included the XPNPEP2 candidate gene with a
two-point LOD score of 2.15 (fig. 2b).
We proceeded to genotype cohort 2 (fig. 1b) for 11
genome-scanned microsatellite markers covering the
four regions above and the XPNPEPL candidate gene
(table 1). Heritability of plasma APP activity for all eight
pedigrees combined was estimated at 33.6%  25.1%
SD, . Analyses of the combined genotype dataPp .0452
from cohorts 1 and 2 produced a maximum two-point
LOD score of 3.75 for the marker XPNPEP2-CA (table
1). Review of the linkage data strongly suggested that
the XPNPEP2 locus is a major genetic factor controlling
APP activity in our families, despite no mutation having
been found in the initial mutation screening experiments.
This locus, however, is not the only regulator of APP
activity, as multipoint linkage analysis in cohort 1 (fig.
2a) provided strong linkage to chromosome 6 (LODp
3.47), but the linkage signal was greatly reduced in com-
bined analyses of both cohorts (LODp 1.43). Our link-
age analysis also provided positive linkage to loci on
chromosomes 8 and 9. Further investigation of these loci
is necessary to either confirm or reject linkage.
Mutation Screening of the XPNPEP2 Locus
Given evidence of strong linkage to the XPNPEP2
locus, we sequenced the coding regions of this candidate
gene in all available AE-ACEi cases with APP activities
!10 units. A coding deletion in XPNPEP2 was detected
in the proband of pedigree VI (fig. 1b) (not included in
the initial mutation screening experiments) who first
suffered an anaphylactoid reaction (AR) associated
with ACEi during hemodialysis and subsequently suf-
fered an AE-ACEi episode. The 175-bp genomic deletion
(g.2953-3127del) includes 16 bp at the 3′ end of exon
2, the donor splice site and a fragment of the down-
stream intron (fig. 3a). The deleted allele is also present
in three relatives of this AE/AR-ACEi patient, who all
have negligible or reduced plasma APP activities (fig. 3b).
The two men with relatively high plasma APP activities
in this family each have a normal copy of this gene. This
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Figure 3 Coding deletion in XPNPEP2. a, The deleted genomic
region of 175 bp consists of 16 bp of exon 2 (in blue), the 3′ donor
splice site (in green) and intronic sequences. b, The deleted allele (DEL)
is present in four members of this pedigree who have negligible or
reduced (in one female heterozygote) plasma APP activity. The two
men with normal alleles (wt) both have high APP measurements. c,
The deletion results in an abnormally spliced mRNA transcript coding
for a premature stop codon that is predicted to translate into a severely
truncated protein of 38 amino acids. This short peptide would not be
membrane-bound because it lacks a glycosylphosphatidylinsitol (GPI)
anchor attached to the alanine (A) at position 650.
deletion was not found in other AE-ACEi cases or con-
trols included in this study.
Total RNA from cultured lymphoblastoid cells of the
AE/AR-ACEi male was used to determine the effects of
this deletion on the mRNA. Sequencing of his cDNA
revealed an erroneously spliced transcript missing exon
2 and a segment of exon 3 (314_431del). This mutant
transcript encodes a premature stop codon, which pre-
sumably translates into a truncated protein of 38 amino
acids that is significantly shorter than the wild-type
mAPP of 674 amino acids (fig. 3c). The first 21 amino
acids of the protein constitute the signal peptide for the
human mAPP, as previously predicted by the SignalP
program, and are consequently cleaved off in the mature
protein (Nielsen et al. 1997). The mutant protein lacks
the predicted active site residues involved in metal ion
coordination and proton shuttling, as well as a glyco-
sylphosphatidylinsitol (GPI) anchor (Molinaro et al.
2004).
Next, we sequenced upstream regions of XPNPEP2
that are highly conserved in the mouse (UCSC; April
2002 freeze) to identify potential regulatory variants. We
identified one SNP (C-2399A; rs3788853) that segre-
gates in seven of our eight linkage families (genotypes
shown in fig. 1). The A allele is absent only in the ped-
igree segregating the coding deletion described above.
The two probands in pedigrees I and V also lack the A
allele, which segregates in their families. Interestingly,
only pedigree I contributes to the linkage signal at the
XPNPEP2_CA marker (LOD p 0.99). We further se-
quenced 3 kb upstream, 1 kb downstream, and the cod-
ing region of XPNPEP2 in all AE-ACEi patients with
the A allele, but did not detect any other sequence var-
iations that might be in linkage disequilibrium with the
C-2399A SNP.
The MatInspector program (Genomatix Suite) pre-
dicts that this substitution potentially affects the binding
sites of two trans-acting elements: hepatic nuclear factor
4 (HNF-4) and peroxisome proliferator-activated recep-
tors/retinoid X receptor (PPAR/RXR) heterodimer. The
biological significance of this SNP remains to be deter-
mined. We have conducted quantitative RT-PCR and
northern blots without success because of the low ex-
pression of XPNPEP2 in human lymphoblastoid cells
(Venema et al. 1997). We have yet to ascertain more
relevant tissues (i.e., kidney and lung) for functional
analysis.
Measured Genotype Analysis of the C-2399A SNP
To evaluate the extent to which the C-2399A SNP
accounts for the linkage observed at the XPNPEP2 lo-
cus, we repeated linkage analysis at the XPNPEP2_CA
microsatellite marker after regressing out the effect of
the C-2399A SNP association by including it as a co-
variate in the linkage model (Almasy and Blangero
2004). The trait mean calculated on the seven pedigrees
segregating the SNP (fig. 1) was 17.25 units. The stan-
dard deviation in the model with the SNP as covariate
was 5.55, compared with 6.70 in the model without the
SNP as a covariate, and the proportion of variance ex-
plained by the covariate SNP was 0.3149. The beta term
for the SNP genotypes in the model was 4.67. The
SNP upstream of XPNPEP2 was significant as a covar-
iate in the model (P ! .0001). When all pedigrees were
used except family VI, which segregates the XPNPEP2
coding deletion, the linkage signal diminished substan-
tially in two-point linkage at the microsatellite marker
XPNPEP2_CA, from LODp 3.24 to LODp 0.54. This
marked diminution in LOD score indicates that the link-
age signal for plasma APP activity at this locus is mostly
accounted for by the C-2399A SNP association.
Association of the C-2399A SNP with AE-ACEi
We genotyped 20 independent AE-ACEi cases and 60
unrelated, matching controls for the C-2399A SNP (ta-
ble 2). The A allele was present in 8 of the 20 AE patients
(table A1 [online only]). By allele counting, the A allele
was found at a frequency of 11.1% in our controls and
27.3% in our AE-ACEi cases. Genotype analysis in cases
versus controls, where the male hemizygote is considered
to be equivalent to the female homozygote, yields a
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(Armitage trend test) when comparing AEPp .0364
cases to population controls.
Discussion
This report provides evidence that variable plasma APP
activity is partially regulated by genetic factors. We es-
timated that 34% of the phenotypic variation in our
linkage families results from genotypic differences. Link-
age analysis significantly identified a QTL (LODp 3.75)
near XPNPEP2, a candidate gene encoding mAPP. De-
spite the absence of mutations detected in the initial
gene-screening experiments, further investigation of this
locus identified two sequence variations. The genomic
deletion segregating in pedigree VI results in an erro-
neously spliced transcript that is predicted to translate
into a severely truncated protein. The C-2399A SNP
genotype significantly accounts for the linkage signal at
this QTL and is significantly associated with AE-ACEi
( ). No other variants that may be in linkagePp .0364
disequilibrium with the A allele were found at this locus
in additional sequencing experiments, further suggesting
that this SNP may be responsible for the observed re-
duction in plasma APP activity.
The above variants were found in 9 of 20 AE-ACEi
cases (table A1 [online only]). This suggests that the low
plasma APP activity observed in additional AE-ACEi
patients may result from other genetic loci or environ-
mental factors. Our multipoint variance-component
linkage analysis of cohort 1 provided evidence of sig-
nificant linkage to a locus on chromosome 6 (LOD p
3.47) and positive linkage to loci on chromosomes 8
and 9. Multipoint linkage analysis including cohort 2,
however, reduced linkage to the chromosome 6 locus
(LODp 1.43), as well as the LOD scores for the other
two autosomal loci. Genotyping of additional markers
at these loci in more families are necessary to either
confirm or reject linkage.
Given that a third of our AE patients have normal
plasma APP activity (20 units), this quantitative trait
clearly explains a fraction of the AE risk associated with
ACEi therapy. Individuals who are not genetically pre-
disposed to have low APP activity may develop AE-
ACEi due to nonspecific inhibition of APP by certain
kinds of ACEi drugs (Hooper et al. 1992) or other un-
identified causes. Other potential risk factors include
elevated levels of the sensory neuropeptide substance P,
which correlate with reduced amounts of dipeptidyl
peptidase IV activity (Ferreira et al. 2000; Lefebvre et
al. 2002). In addition, clinical trials for new vasopep-
tidase inhibitors (that inhibit NEP and ACE) result in
higher AE incidence than with ACE inhibition alone,
suggesting that NEP activity may play a role in AE risk.
Furthermore, other, nongenetic factors (i.e., smoking
and estrogen replacement) may contribute to AE-ACEi
risk.
Our study confirms previously published data show-
ing that reduced plasma APP activity is a relatively com-
mon phenotype in the general population (Lefebvre et
al. 2002). Other than predisposition to AE-ACEi, no
clinical phenotype has been associated with low APP
activity to date. This suggests that its physiological role
may be nonessential or that there is functional redun-
dancy. Furthermore, certain ACEi patients with low
APP activity do not develop AE during therapy. This
suggests that factors (i.e., environmental triggers) acting
in pathways other than des-Arg9-BK degradation may
contribute to AE risk.
Finally, low APP activity may determine risk for other
ACEi-associated adverse effects. We previously reported
an association between reduced plasma APP activity and
anaphylactoid reactions during hemodialysis induced by
ACEi therapy (Blais et al. 1999a). Further genetic in-
vestigations are necessary to determine if variants in the
XPNPEP2 locus, such as those described here, play a
role in AR-ACEi risk. Other adverse reactions associ-
ated with ACEi therapy include chronic cough, which
affects ∼10%–15% of ACEi patients. It would be in-
teresting to further characterize plasma APP activity in
these patients and screen XPNPEP2 as a candidate sus-
ceptibility gene for these side effects of ACEi.
In conclusion, this report demonstrates that genetic
variants at the XPNPEP2 locus are partially responsible
for reduced plasma APP activity. Furthermore, we show
a significant association between the C-2399A poly-
morphism and AE-ACEi. Thus, we have successfully
mapped a QTL that may, in part, predict susceptibility
to a potentially fatal adverse reaction associated with
one of the most commonly used drugs worldwide. Our
study represents a potential application of pharmaco-
genomics in health care, a field destined to transform
medical care, but in which there have been few successes
to date. Our findings, in addition to further studies, may
facilitate the rational design of safer drugs for treating
cardiovascular diseases, as well as clinical assays for
predicting individuals who are genetically more liable
to develop AE associated with ACEi or other vasopep-
tidase inhibitors.
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